Edwards Lifesciences (EW) Cash from Financing Activities (2009 - 2026)
Edwards Lifesciences (EW) posted quarterly Cash from Financing Activities of -$451.2 million for Q1 2026, down 74.88% year-over-year from -$1.8 billion in Q1 2025, and down 3857.89% quarter-over-quarter from -$11.4 million in Q4 2025.
Edwards Lifesciences (EW) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Edwards Lifesciences' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$451.2 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 74.88% year-over-year to -$451.2 million; the TTM figure through Mar 2026 stood at -$1.2 billion (up 11.72% YoY), while the FY2025 annual figure was -$956.8 million, up 2.67% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$451.2 million, down from -$11.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $61.7 million in Q1 2024, with the low at -$976.7 million in Q3 2024.
- The 5-year median for Cash from Financing Activities is -$206.6 million (2023), against an average of -$275.7 million.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities tumbled 1252.26% in 2022, then surged 154.55% in 2025.
- Edwards Lifesciences' Cash from Financing Activities stood at -$838.4 million in 2022, then surged by 50.72% to -$413.2 million in 2023, then jumped by 106.92% to $28.6 million in 2024, then sank by 139.86% to -$11.4 million in 2025, then tumbled by 3857.89% to -$451.2 million in 2026.
- Business Quant data shows EW's Cash from Financing Activities at -$451.2 million in Q1 2026, -$11.4 million in Q4 2025, and -$740.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.52 Bn | 193.92 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 129.55 Bn | 126.07 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 119.60 Bn | 110.38 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 73.64 Bn | 73.10 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 52.33 Bn | 48.08 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.69 Bn | 32.74 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 34.10 Bn | 31.99 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.43 Bn | 23.11 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Zimmer Biomet Holdings | 19.34 Bn | 18.93 Bn | 1.54 Bn | -271.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -300,000.00 |
| Jun 30, 2026 | -300,000.00 |
| Mar 31, 2026 | -451.20 Mn |
| Mar 31, 2026 | -451.20 Mn |
| Dec 31, 2025 | -11.40 Mn |
| Dec 31, 2025 | -11.40 Mn |
| Sep 30, 2025 | -740.10 Mn |
| Sep 30, 2025 | -740.10 Mn |
| Jun 30, 2025 | 52.70 Mn |
| Jun 30, 2025 | 52.70 Mn |
| Mar 31, 2025 | -258.00 Mn |
| Mar 31, 2025 | -258.00 Mn |
| Dec 31, 2024 | 28.60 Mn |
| Dec 31, 2024 | 28.60 Mn |
| Sep 30, 2024 | -976.70 Mn |
| Sep 30, 2024 | -976.70 Mn |
| Jun 30, 2024 | -96.60 Mn |
| Jun 30, 2024 | -96.60 Mn |
| Mar 31, 2024 | 61.70 Mn |
| Mar 31, 2024 | 61.70 Mn |